706 related articles for article (PubMed ID: 20843746)
1. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
Reprod Biomed Online; 2011 Feb; 22 Suppl 1():S23-31. PubMed ID: 21575846
[TBL] [Abstract][Full Text] [Related]
3. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
[TBL] [Abstract][Full Text] [Related]
4. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
Corifollitropin Alfa Dose-finding Study Group
Hum Reprod; 2008 Nov; 23(11):2484-92. PubMed ID: 18684735
[TBL] [Abstract][Full Text] [Related]
5. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.
Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM
J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522
[TBL] [Abstract][Full Text] [Related]
6. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women.
Corifollitropin alfa Ensure Study Group
Reprod Biomed Online; 2010 Jul; 21(1):66-76. PubMed ID: 20483664
[TBL] [Abstract][Full Text] [Related]
7. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
[TBL] [Abstract][Full Text] [Related]
8. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.
Blockeel C; Polyzos NP; Derksen L; De Brucker M; Vloeberghs V; van de Vijver A; De Vos M; Tournaye H
Hum Reprod; 2014 Jul; 29(7):1500-7. PubMed ID: 24813196
[TBL] [Abstract][Full Text] [Related]
9. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.
Croxtall JD; McKeage K
BioDrugs; 2011 Aug; 25(4):243-54. PubMed ID: 21815699
[TBL] [Abstract][Full Text] [Related]
10. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.
Fauser BC; Mannaerts BM; Devroey P; Leader A; Boime I; Baird DT
Hum Reprod Update; 2009; 15(3):309-21. PubMed ID: 19182099
[TBL] [Abstract][Full Text] [Related]
11. Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome.
Bonduelle M; Mannaerts B; Leader A; Bergh C; Passier D; Devroey P
Hum Reprod; 2012 Jul; 27(7):2177-85. PubMed ID: 22587997
[TBL] [Abstract][Full Text] [Related]
12. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
[TBL] [Abstract][Full Text] [Related]
14. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
16. Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial.
Mardešič T; Mannaerts B; Abuzeid M; Levy M; Witjes H; Fauser BC;
Reprod Biomed Online; 2014 Apr; 28(4):462-8. PubMed ID: 24581989
[TBL] [Abstract][Full Text] [Related]
17. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
[TBL] [Abstract][Full Text] [Related]
18. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
Boostanfar R; Mannaerts B; Pang S; Fernandez-Sanchez M; Witjes H; Devroey P;
Fertil Steril; 2012 Jun; 97(6):1351-8. PubMed ID: 22459628
[TBL] [Abstract][Full Text] [Related]
19. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
20. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study.
Blockeel C; De Vos M; Verpoest W; Stoop D; Haentjens P; Devroey P
Hum Reprod; 2009 Nov; 24(11):2910-6. PubMed ID: 19617207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
